https://www.sec.gov/Archives/edgar/data/1835597/000119312522106884/d235586ds1.htm
Optimistic that RP11 is the real deal that’ll benefit patients, science and PYC/shareholders.
Working on that assumption is mgt believing also their delivery platform is the real deal ushering a new delivery paradigm?
Then maybe it’s buying time to patent up as many leads as possible before more competitors/industry mirror our approach like the above Nasdaq IPO seeking US$100m infusion.
Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-34
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 33500 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 5600 | 1 |
View Market Depth
| Last trade - 09.13am 08/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable